Publication Name	World Journal of Gastroenterology
Manuscript ID	18311
Country	Japan

Received	2015-04-16 09:03
Peer-Review Started	2015-04-18 13:52
To Make the First Decision	2015-05-18 13:02
Return for Revision	2015-05-20 10:26
Revised	2015-05-28 14:32
Second Decision	2015-07-27 19:59
Accepted by Journal Editor-in-Chief	2015-07-28 04:30
Accepted by Executive Editor-in-Chief	2015-08-31 16:19
Articles in Press	2015-08-31 16:19
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-09-21 12:03
Publish the Manuscript Online	2015-10-23 15:45

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Hidetoshi Takedatsu, Keiichi Mitsuyama and Takuji Torimura
Funding Agency and Grant Number	Funding Agency Grant Number Japanese Society for the Promotion of Science, KAKENHI Grant 25460963
Corresponding Author	Hidetoshi Takedatsu, MD, PhD, Division of Gastroenterology, Department of Medicine, Kurume Univer­sity School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan. takedatsu_hidetoshi@kurume-u.ac.jp
Key Words	Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Nanomedicine; Small interfering RNA; Antisense oligonucleotide
Core Tip	Crohn’s disease and ulcerative colitis are important categories of human inflammatory bowel disease (IBD). IBD treatment generally involves attempting to inhibit pathogenic factors of the in-flammatory cascade. Recent studies suggest that nanomedicine provides advantages over conventional treatments for the treatment of intestinal inflammation because nano-size molecules can effectively penetrate epithelial and inflammatory cells. The efficacy and usefulness of the nanomedicine treatments reviewed in this manuscript have been validated in experimental colitis models and clinical trials. Nanomedicine is therefore expected to become a new therapeutic approach to the treatment of IBD.
Publish Date	2015-10-23 15:45
Citation	Takedatsu H, Mitsuyama K, Torimura T. Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease. World J Gastroenterol 2015; 21(40): 11343-11352
URL	http://www.wjgnet.com/1007-9327/full/v21/i40/11343.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i40.11343

Full Article (PDF)	WJG-21-11343.pdf
Full Article (Word)	WJG-21-11343.doc
Manuscript File	18311-Review.doc
Answering Reviewers	18311-Answering reviewers.pdf
Audio Core Tip	18311-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	18311-Conflict-of-interest statement.pdf
Copyright License Agreement	18311-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	18311-Language certificate.pdf
Peer-review Report	18311-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	18311-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	18311-Scientific misconduct check.pdf
Scientific Editor Work List	18311-Scientific editor work list.pdf